About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$23.05
Change (%) Stock is Up 0.29 (1.27%)
Volume166,249
Data as of 07/17/18 10:39 a.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $23.05 with a 52 week high of $23.85 and a 52 week low of $7.78.

Recent News

Natera Announces Pricing of Follow-On Offering - 07/12/18
SAN CARLOS, Calif., July 12, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the pricing of its underwritten public offering of 4,500,000 shares... More»
Natera Launches Proposed Follow-On Offering - 07/10/18
SAN CARLOS, Calif., July 10, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the launch of a proposed follow-on public offering of $75,000,000 o... More»
Natera To Host Investor Conference Call to Discuss Strategic Roadmap in Organ Transplantation and Oncology - 06/21/18
Commercializing Core Cell-free DNA Technology Beyond Reproductive Health SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in genetic testing and cell-free DNA analysis, will share data and roadmap for its e... More»
Natera Develops Powerful Kidney Transplant Rejection Biomarker - 06/21/18
Data to be Presented at The Transplantation Society International Congress in Madrid on July 3, 2018 SAN CARLOS, Calif., June 21, 2018 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA analysis, announces a powerful new kidn... More»
Natera and Institut Jules Bordet Announce Collaboration in Neoadjuvant Breast Cancer - 06/19/18
Signatera assay to be used in research to evaluate treatment response and minimal residual disease SAN CARLOS, Calif., June 19, 2018 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a resear... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.
Shareholder Tools